FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013213051> ?p ?o ?g. }

• W3013213051 endingPage "PR02" @default.
• W3013213051 startingPage "PR02" @default.
• W3013213051 abstract "Abstract Background: NRG1 fusions are oncogenic drivers of various cancers including pancreatic and lung adenocarcinomas. NRG1 fusion proteins bind to HER3, leading to HER2/HER3 heterodimerization, increased downstream signaling, and tumor growth. MCLA-128 is a bispecific antibody directed against HER2 and HER3 that docks on HER2 and blocks ligand binding to HER3, thereby preventing downstream signaling. In contrast to tyrosine kinase inhibitors or anti-HER3 monoclonal antibodies, MCLA-128 was shown in vitro and in vivo to potently inhibit ligand-driven tumor growth at high NRG1 levels present in NRG1 fusion-positive cancers. MCLA-128 offers a novel therapeutic paradigm for NRG1 fusion-positive cancers. MCLA-128 has a very well tolerated safety profile with &lt;5% of patients reporting grade 3-4 suspected related AEs, and a notable lack of cardiotoxicity and severe gastrointestinal or skin toxicity. Methods: Cell line/xenograft models with NRG1 fusions (MDA-MB-175, OV5383, OV10-0050) were treated with MCLA-128. Patients with cancers harboring NRG1 fusions were identified using prospective molecular profiling by DNA/RNA-based next-generation sequencing (NGS). Patients with NRG1 fusion-positive tumors were treated with MCLA-128 (750 mg intravenously, every 2 weeks) on FDA-approved single-patient protocols. Results: Treatment with MCLA-128 inhibited proliferation of NRG1-fusion positive cell lines in vitro and resulted in rapid tumor shrinkage in NRG1 fusion-positive xenograft models in vivo. NGS identified 29 patients with NRG1 fusions across 8 tumor types (pancreas, lung, breast, sarcoma, prostate, gallbladder, unknown primary, and DLBCL). Of these 29 patients, 3 with chemotherapy-resistant metastatic cancer were treated with MCLA-128 and experienced dramatic clinical and radiographic responses. A 52-year-old man with ATP1B1-NRG1 fusion-positive pancreatic ductal adenocarcinoma (PDAC) with liver metastases, worsening fatigue, and weight loss, achieved rapid clinical and pharmacodynamic responses (CA19-9 decrease from 262 to 56). Imaging at 8 weeks demonstrated a partial response (-44%) by RECIST v1.1 and a complete response by PERCIST. A 34-year-old man with ATP1B1-NRG1 fusion-positive PDAC and longstanding tumor-associated abdominal pain also achieved rapid resolution of his pain, and normalization of CA 19-9 (418 to 11) upon treatment with MCLA-128. Imaging at 6 weeks showed tumor reduction (-22%) and that the liver metastases were non-FDG avid. A third patient with CD74-NRG1 fusion-positive non-small cell lung cancer (NSCLC) metastatic to the brain was started on MCLA-128. Despite progression on 6 prior lines of systemic therapy including afatinib, he rapidly responded to MCLA-128 with scans showing a partial response (-33%) by RECIST v1.1 at 8 weeks and tumor shrinkage in the brain. All patients remain on therapy (6+ months into treatment for the PDAC patients, 2+ months for the NSCLC patient) with no substantial toxicity. Conclusions: MCLA-128 leads to clinical responses in patients with NRG1 fusion-positive cancers through inhibition of ligand-driven activation of the HER3 pathway. A global, multicenter phase 2 basket trial for NRG1 fusion-positive cancers is now accruing patients. Citation Format: Alison M Schram, Eileen M O’Reilly, Romel Somwar, Ryma Benayed, Sara Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, David Maussang, Ernesto Wasserman, Marc Ladanyi, David M Hyman, L. Andres Sirulnik, Alexander Drilon. Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr PR02. doi:10.1158/1535-7163.TARG-19-PR02" @default.
• W3013213051 created "2020-04-03" @default.
• W3013213051 creator A5001595006 @default.
• W3013213051 creator A5002467795 @default.
• W3013213051 creator A5009070223 @default.
• W3013213051 creator A5019697738 @default.
• W3013213051 creator A5021320808 @default.
• W3013213051 creator A5030479930 @default.
• W3013213051 creator A5040540899 @default.
• W3013213051 creator A5046345178 @default.
• W3013213051 creator A5049287423 @default.
• W3013213051 creator A5063199354 @default.
• W3013213051 creator A5068193017 @default.
• W3013213051 creator A5076438320 @default.
• W3013213051 creator A5088495181 @default.
• W3013213051 creator A5089952390 @default.
• W3013213051 date "2019-12-01" @default.
• W3013213051 modified "2023-09-25" @default.
• W3013213051 title "Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in <i>NRG1</i> fusion-positive cancers" @default.
• W3013213051 doi "https://doi.org/10.1158/1535-7163.targ-19-pr02" @default.
• W3013213051 hasPublicationYear "2019" @default.
• W3013213051 type Work @default.
• W3013213051 sameAs 3013213051 @default.
• W3013213051 citedByCount "20" @default.
• W3013213051 countsByYear W30132130512020 @default.
• W3013213051 countsByYear W30132130512021 @default.
• W3013213051 countsByYear W30132130512022 @default.
• W3013213051 countsByYear W30132130512023 @default.
• W3013213051 crossrefType "journal-article" @default.
• W3013213051 hasAuthorship W3013213051A5001595006 @default.
• W3013213051 hasAuthorship W3013213051A5002467795 @default.
• W3013213051 hasAuthorship W3013213051A5009070223 @default.
• W3013213051 hasAuthorship W3013213051A5019697738 @default.
• W3013213051 hasAuthorship W3013213051A5021320808 @default.
• W3013213051 hasAuthorship W3013213051A5030479930 @default.
• W3013213051 hasAuthorship W3013213051A5040540899 @default.
• W3013213051 hasAuthorship W3013213051A5046345178 @default.
• W3013213051 hasAuthorship W3013213051A5049287423 @default.
• W3013213051 hasAuthorship W3013213051A5063199354 @default.
• W3013213051 hasAuthorship W3013213051A5068193017 @default.
• W3013213051 hasAuthorship W3013213051A5076438320 @default.
• W3013213051 hasAuthorship W3013213051A5088495181 @default.
• W3013213051 hasAuthorship W3013213051A5089952390 @default.
• W3013213051 hasConcept C104317684 @default.
• W3013213051 hasConcept C121608353 @default.
• W3013213051 hasConcept C123894998 @default.
• W3013213051 hasConcept C126322002 @default.
• W3013213051 hasConcept C150903083 @default.
• W3013213051 hasConcept C170493617 @default.
• W3013213051 hasConcept C207001950 @default.
• W3013213051 hasConcept C40767141 @default.
• W3013213051 hasConcept C42362537 @default.
• W3013213051 hasConcept C502942594 @default.
• W3013213051 hasConcept C55493867 @default.
• W3013213051 hasConcept C71924100 @default.
• W3013213051 hasConcept C86803240 @default.
• W3013213051 hasConceptScore W3013213051C104317684 @default.
• W3013213051 hasConceptScore W3013213051C121608353 @default.
• W3013213051 hasConceptScore W3013213051C123894998 @default.
• W3013213051 hasConceptScore W3013213051C126322002 @default.
• W3013213051 hasConceptScore W3013213051C150903083 @default.
• W3013213051 hasConceptScore W3013213051C170493617 @default.
• W3013213051 hasConceptScore W3013213051C207001950 @default.
• W3013213051 hasConceptScore W3013213051C40767141 @default.
• W3013213051 hasConceptScore W3013213051C42362537 @default.
• W3013213051 hasConceptScore W3013213051C502942594 @default.
• W3013213051 hasConceptScore W3013213051C55493867 @default.
• W3013213051 hasConceptScore W3013213051C71924100 @default.
• W3013213051 hasConceptScore W3013213051C86803240 @default.
• W3013213051 hasIssue "12_Supplement" @default.
• W3013213051 hasLocation W30132130511 @default.
• W3013213051 hasOpenAccess W3013213051 @default.
• W3013213051 hasPrimaryLocation W30132130511 @default.
• W3013213051 hasRelatedWork W2002915072 @default.
• W3013213051 hasRelatedWork W2003690696 @default.
• W3013213051 hasRelatedWork W2031731997 @default.
• W3013213051 hasRelatedWork W2080981165 @default.
• W3013213051 hasRelatedWork W2109763600 @default.
• W3013213051 hasRelatedWork W2365364931 @default.
• W3013213051 hasRelatedWork W2418638721 @default.
• W3013213051 hasRelatedWork W2982294827 @default.
• W3013213051 hasRelatedWork W3011804615 @default.
• W3013213051 hasRelatedWork W4362506631 @default.
• W3013213051 hasVolume "18" @default.
• W3013213051 isParatext "false" @default.
• W3013213051 isRetracted "false" @default.
• W3013213051 magId "3013213051" @default.
• W3013213051 workType "article" @default.